News and Announcements
SUDA Update: Funding for Second Phase III Study of ArTiMist™, BIO-Europe Spring International Partnering Conference & More
- Published April 19, 2016 10:58AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th Apriul 2016, ASX Announcement
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces an update on its business development activities. The Company is in advanced negotiations with multiple pharmaceutical companies regarding licensing its first-in-class oral sprays in a variety of countries. Subject to successful contact negotiations, SUDA aims to finalise agreements within the next few months. Discussions with philanthropic groups and other providers on non-dilutive funding for a second Phase III study of ArTiMist™ in paediatric malaria are also progressing.
The business development team attended the BIO-Europe Spring international partnering conference, which was held in Stockholm, Sweden, on 4-6 April 2016. The team has one-to-one meetings with over 30 pharmaceutical companies.
To view the full article please click on the button below.